Canaccord Genuity raises Aclaris Therapeutics target price to $13 from $10
ACRS•Canaccord Genuity raised its target price for Aclaris Therapeutics to $13 from $10.
Related News
Dana Inc: UBS cuts target price to $34 from $36
DAN•
Textron's Bell secures order for additional helicopters from Global Medical Response
TXT•
Bally's says $260 million fine does not render Star Entertainment insolvent
BALY•
Restaurant Brands International posts Q3 system-wide sales up 6.2%
QSR•
WEX Q3 2026 adjusted net income per diluted share rises 34% to $6.13
WEX•